Novo Integrated Sciences SG&A Expenses 2012-2024 | NVOS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Novo Integrated Sciences sg&a expenses from 2012 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Novo Integrated Sciences SG&A Expenses 2012-2024 | NVOS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Novo Integrated Sciences sg&a expenses from 2012 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Fresenius SE (FSNUY)	$21.3B
Quest Diagnostics (DGX)	$18.2B
DaVita (DVA)	$14.1B
Encompass Health (EHC)	$9.9B
Chemed (CHE)	$8.3B
Elanco Animal Health (ELAN)	$5.9B
Option Care Health (OPCH)	$5.2B
RadNet (RDNT)	$4.8B
LifeStance Health (LFST)	$3.1B
Amedisys (AMED)	$3B
Addus HomeCare (ADUS)	$2.2B
Astrana Health (ASTH)	$2B
U.S Physical Therapy (USPH)	$1.3B
Aveanna Healthcare Holdings (AVAH)	$935M
Pennant (PNTG)	$935M
Atai Life Sciences (ATAI)	$356M
Bioqual (BIOQ)	$54M
Daxor (DXR)	$38M
Ontrak (OTRK)	$7M
MEDIROM Healthcare Technologies (MRM)	$5M
IMAC Holdings (BACK)	$1M
Psychemedics (PMD)	$0M